The below is taken from Krushingit’s post on the CHM thread but thought it was relevant as it relates to pancreatic treatments. Relates to a company (Nasdaq) called Revolution Medicines which designs inhibitors for RAS proteins. Different mode of action but interesting data (MC over $7B). Hard to compare as it’s after a previous treatment but our molecule is already seemingly pushing out the SOC survival rates. DYOR of course!
Ann: Amplia Appoints Dr Jason Lickliter as Chief Medical Officer, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.005(2.13%) |
Mkt cap ! $116.7M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.5¢ | 22.5¢ | $2.020M | 8.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 230225 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 778184 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |